Background This trial was designed to evaluate the activity and safety of ganetespib in
combination with docetaxel in advanced non-small cell lung cancer (NSCLC) and to identify …

… when combined with platinum-based chemotherapy in first-line advanced non-small-cell
lung cancer. We report the final overall survival (OS) analysis from the phase III AVAiL trial. …

… cases of lung cancer diagnosed annually, small-cell lung cancer (SCLC) comprises
approximately 13%, or an estimated 25,000 cases. Compared with other forms of lung cancer, SCLC …

… A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin
as … advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer. 2013; 14: 215-223 …

… phase III INTEREST trial, 1,466 pretreated patients with advanced non–small cell lung cancer
(NSCLC) were randomly … prospectively analyzed available tumor biopsies to investigate …

Purpose This phase II, open-label, parallel-group study compared gefitinib with vinorelbine
in chemotherapy-naïve elderly patients with advanced non–small-cell lung cancer (NSCLC)…

… The primary objective of this randomized phase II study … stage IV or recurrent NS NSCLC.
Secondary objectives included assessment of time to progressive disease (TtPD), OS, tumor …

Background: Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for
limited disease small cell lung cancer (LD SCLC). Twice daily TRT is well documented, but …

… in patients with advanced non–small cell lung cancer. During the trial, studies of tyrosine
kinase inhibitors in non–small cell lung cancer reported that epidermal growth factor receptor …

Introduction This study compared survival without toxicity in patients with advanced, nonsquamous
non-small cell lung cancer who were treated with first-line pemetrexed/carboplatin or …